Ignite Creation Date:
2024-05-06 @ 7:38 AM
Last Modification Date:
2024-10-26 @ 11:50 AM
Study NCT ID:
NCT02575261
Status:
WITHDRAWN
Last Update Posted:
2020-07-16
First Post:
2015-09-29
Brief Title:
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Sponsor:
Fuda Cancer Hospital Guangzhou
Organization:
Fuda Cancer Hospital Guangzhou
Study Overview
Official Title:
Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma
Status:
WITHDRAWN
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients
Detailed Description:
Chimeric antigen receptor CAR is a recombinant receptor with both antigen-binding and T cell activating functions Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy especially in dealing with patients of hematologic malignancies and solid malignant tumorsThis study design a novel specific Chimeric antigen receptor aiming at EphA2 antigenAfter CAR-T cell infusionAt periodic intervals the investigators will evaluate clinical symptoms Improved conditions of this diseaseThrough this studythe investigators will evaluate the safty and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None